Security Snapshot

Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) Institutional Ownership

CUSIP: 92511W108

13F Institutional Holders and Ownership History from Q2 2018 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.70

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, $0.0001 par value
Symbol
VRCA on Nasdaq
Shares outstanding
92,448,158
Price per share
$0.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • VRCA - Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 92511W108.
  • Latest finished 13F holder period is not available.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $301 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Security key

92511W108

Latest holder period

n/a

13F holders

13D/G owners

3

CIK / CUSIP context first

VRCA full holder history Verrica Pharmaceuticals Inc. SEC filings Verrica Pharmaceuticals Inc. company facts Verrica Pharmaceuticals Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Caligan Partners LP 10% $7,769,760 15,856,653 Caligan Partners LP 31 Dec 2024
ARMISTICE CAPITAL, LLC 10% 0% $7,480,813 +$81,611 9,235,571 +1.1% Armistice Capital, LLC 31 Mar 2025
PERCEPTIVE ADVISORS LLC 1.6% -70% $725,926 -$1,592,338 1,481,481 -69% Perceptive Advisors LLC 31 Mar 2025

Institutional Holders of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$301 $0.70 0
2025 Q3 568 $301 -$13,341,086 $0.53 1
2025 Q2 24,695,954 $13,342,110 -$2,100,389 $0.53 52
2025 Q1 29,469,428 $13,048,369 -$1,283,534 $0.44 72
2024 Q4 30,028,982 $21,000,938 +$9,292,302 $0.70 79
2024 Q3 14,834,226 $21,508,548 -$32,397,531 $1.45 77
2024 Q2 18,643,979 $135,914,431 +$6,591,352 $7.29 73
2024 Q1 17,749,027 $105,073,968 -$1,725,785 $5.92 61
2023 Q4 18,001,640 $131,764,630 +$23,720,799 $7.32 62
2023 Q3 15,050,197 $58,469,992 +$1,486,122 $3.88 66
2023 Q2 14,600,620 $84,243,730 +$9,028,680 $5.77 63
2023 Q1 12,947,808 $84,159,481 +$15,090,414 $6.50 60
2022 Q4 10,821,432 $29,758,148 -$1,572,823 $2.75 49
2022 Q3 10,245,689 $29,916,489 -$2,471,402 $2.92 46
2022 Q2 11,327,999 $21,748,342 +$3,203,973 $1.92 51
2022 Q1 8,884,415 $72,064,740 -$552,806 $8.11 47
2021 Q4 8,952,454 $81,996,119 -$7,321,125 $9.16 43
2021 Q3 9,169,116 $114,604,238 -$9,413,538 $12.50 49
2021 Q2 9,937,044 $112,291,153 -$1,689,115 $11.30 53
2021 Q1 9,927,525 $150,401,616 +$14,713,541 $15.15 51
2020 Q4 8,959,095 $103,116,539 -$681,856 $11.51 44
2020 Q3 8,930,028 $69,119,527 +$677,068 $7.74 46
2020 Q2 8,804,592 $96,937,883 -$278,437 $11.01 44
2020 Q1 8,833,450 $96,547,906 -$4,771,475 $10.93 45
2019 Q4 9,202,752 $144,059,393 -$4,086,412 $15.89 52
2019 Q3 9,265,491 $136,756,439 +$4,176,491 $14.76 42
2019 Q2 9,017,971 $104,753,394 +$2,578,213 $11.62 40
2019 Q1 8,816,628 $96,977,441 +$5,664,930 $10.81 40
2018 Q4 8,445,077 $68,825,024 -$1,838,933 $8.15 41
2018 Q3 8,239,628 $133,896,000 -$2,329,398 $16.25 45
2018 Q2 8,314,673 $164,045,000 +$164,044,999 $19.73 28
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .